The Lancet Neurology published the results of the phase 3b NOVA study assessing the effectiveness of natalizumab administered every six weeks in the treatment of patients with relapsing-remitting multiple sclerosis.
The results of the NOVA study show that natalizumab given intravenously every six weeks provides a high level of effectiveness in controlling MS activity in patients who switched from the every four weeks dosing regimen. The 6-week schedule has already been approved by the EMA.
- The NOVA study is the first prospective study to evaluate the natalizumab dosing regimen every six weeks in patients with relapsing-remitting MS. It i...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
